Watch Live

Tweet TWEET

Zacks Bull and Bear of the Day Highlights: Apollo Global Management, Agnico-Eagle Mines, IsisPharmaceuticals, GlaxoSmithKline

     Zacks Bull and Bear of the Day Highlights: Apollo Global Management,
     Agnico-Eagle Mines, IsisPharmaceuticals, GlaxoSmithKline and Sanofi

PR Newswire

CHICAGO, April 3, 2013

CHICAGO, April 3, 2013 /PRNewswire/ -- Zacks Equity Research highlights Apollo
Global Management, LLC (NYSE:APO) as the Bull of the Day and Agnico-Eagle
Mines (NYSE:AEM) as the Bear of the Day. In addition, Zacks Equity Research
provides analysis on Isis Pharmaceuticals, Inc. (Nasdaq:ISIS), GlaxoSmithKline
(NYSE:GSK) and Sanofi (NYSE:SNY).

(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)

Full analysis of all these stocks is available at
http://at.zacks.com/?id=2678.

Here is a synopsis of all five stocks:

Bull of the Day:

Ready to plunk down some money with a private equity firm? If you are an
accredited high net worth investor with at least $1 million to risk with the
firm on whatever their latest deal is, you have many quality outfits to choose
from.

But if you're not in "the 1%," there is another path. Many private equity (PE)
firms are also public companies, including Blackstone Group and the infamous
KKR. As an industry group, together with traditional investment management
firms like BlackRock and Franklin Resources, the PE "alternative" asset
managers currently rank in the top 10% of Zacks Industries.

Today we are going to focus on Apollo Global Management, LLC (NYSE:APO), a $3
billion company which grew its total assets under management (AUM) in 2012
from $75 billion to $113 billion.

Apollo operates in three business segments: private equity, capital markets
and real estate. It raises, invests and manages funds on behalf of pension and
endowment funds, as well as other institutional and individual investors.

After a rough year following its March 2011 IPO, the firm started firing on
all rockets, boosting fourth-quarter GAAP earnings an astronomical 1,564%
higher than a year earlier. And this represented a 120% surprise over analyst
expectations.

Bear of the Day:

As long as the price of gold continues to drift lower, it seems earnings
expectations for miners of the yellow metal are following its decline. And in
the high-risk metal mining industry, costs can quickly escalate too.

This week, Agnico-Eagle Mines (NYSE:AEM ) dropped to a Zacks #5 Rank as
analyst 2013 EPS estimates have fallen from $2.44 to $2.04 in the past 60
days. And downward revisions have taken the full-year 2014 down to $2.36 from
$2.80.

Agnico-Eagle Mines Limited is a Toronto-based gold producer with operations in
Canada, Finland and Mexico. The company's LaRonde mine in Quebec is one of
Canada s largest operating gold mines by gold reserves and has provided the
company s foundation for domestic and international expansion.

The company missed expectations in fourth-quarter 2012 with both revenues and
adjusted earnings falling short of the Zacks Consensus Estimate.

Latest Posts on the Zacks Analyst Blog:

Isis Publishes Encouraging Data

Isis Pharmaceuticals, Inc. (Nasdaq:ISIS) recently published encouraging new
data in the journal Circulation Research related to antisense technology. It
was found that antisense targeting of apolipoprotein C-III (apoC-III) showed
significant decline in apoC-III and triglycerides. Both apoC-III and
triglycerides are risk factors associated with cardiovascular diseases.

Isis Pharma currently has an antisense apoC-III inhibitor, ISIS-APOCIII, in
its pipeline. ISIS-APOCIII is being evaluated in a phase II study for the
treatment of severe hypertriglyceridemia. Top-line data from the study are
expected to be released in mid-2013. On completion of the phase II study the
company plans to initiate phase III study on the candidate.

We are impressed by the development of antisense technology and believe that
the number of potential therapeutic applications is enormous. Antisense drugs
may have significant potential to treat a number of diseases where small
molecules and biologic compounds have failed. Although still in its early
stage, antisense technology with mechanisms such as small interfering RNA
(siRNA), RNA interference (RNAi), alternate splicing, and microRNA (mRNA) have
the potential to change how diseases are treated.

Earlier this year, Isis Pharma received a $7.5 million milestone payment from
GlaxoSmithKline (NYSE:GSK). The payment primarily relates to the initiation of
a phase II/III clinical study of ISIS-TTRRx. The study will span 15 months
enrolling 200 patients. Isis is developing ISIS-TTRRx in collaboration with
Glaxo for the potential treatment of transthyretin (TTR) amyloidosis.

We note that Isis Pharma's lead product, Kynamro (mipomersen sodium), received
FDA approval in Jan 2013 for the treatment of familial hypercholesterolemia
(FH). Isis Pharma's partner Sanofi (NYSE:SNY) is marketing the product in the
US. Sanofi is also looking to get the drug approved in the rest of the world
including Europe.

Isis Pharma currently carries a Zacks Rank #3 (Hold).

Get the full analysis of all these stocks by going to
http://at.zacks.com/?id=2649.

About the Bull and Bear of the Day

Every day, the analysts at Zacks Equity Research select two stocks that are
likely to outperform (Bull) or underperform (Bear) the markets over the next
3-6 months.

About the Analyst Blog

Updated throughout every trading day, the Analyst Blog provides analysis from
Zacks Equity Research about the latest news and events impacting stocks and
the financial markets.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative
analysis to help investors know what stocks to buy and which to sell for the
long-term.

Continuous analyst coverage is provided for a universe of 1,150 publicly
traded stocks. Our analysts are organized by industry which gives them keen
insights to developments that affect company profits and stock performance.
Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the
latest analysis from Zacks Equity Research. Subscribe to this free newsletter
today by visiting http://at.zacks.com/?id=7158.

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed
in 1978 by Leonard Zacks. As a PhD from MIT Len knew he could find patterns in
stock market data that would lead to superior investment results. Amongst his
many accomplishments was the formation of his proprietary stock picking
system; the Zacks Rank, which continues to outperform the market by nearly a 3
to 1 margin. The best way to unlock the profitable stock recommendations and
market insights of Zacks Investment

Research is through our free daily email newsletter; Profit from the Pros. In
short, it's your steady flow of Profitable ideas GUARANTEED to be worth your
time! Register for your free subscription to Profit from the Pros at
http://at.zacks.com/?id=4582.

Visit http://www.zacks.com/performance for information about the performance
numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/zacksresearch

Join us on Facebook:
http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Disclaimer: Past performance does not guarantee future results. Investors
should always research companies and securities before making any investments.
Nothing herein should be construed as an offer or solicitation to buy or sell
any security.

Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
support@zacks.com
http://www.zacks.com

SOURCE Zacks Investment Research, Inc.

Website: http://www.zacks.com